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TCT-711
Large Devices for Transcatheter Closure of Atrial Septal Defects in Adult
Patients: the REPERA Multicenter Registry
Felipe Hernandez1, Elvira Barrios1, Lidia de Sousa2, Rosana Hernandez3, Federico
Gimeno4, Jose M de la Torre Hernandez5, Jose M Hernandez6, Juan M Ruiz Nodar7,
Francisco Bosa8, Ignacio Cruz9, Javier Goicolea10, Jose F Diaz11, Felipe Fernandez
Vazquez12, Luis M Teruel13, Jose Moreu14
1Interventional Cardiology, Hospital 12 de Octubre, Madrid, Spain; 2Hospital Santa
Marta, Lisbon, Portugal; 3Hospital San Carlos, Madrid, Spain; 4Hospital Clinico,
Valladolid, Spain; 5Hospital Marques de Valdecilla, Santander, Spain; 6Hospital
Virgen de la Victoria, Malaga, Spain; 7Hospital General, Alicante, Spain; 8Hospital
Universitario, Santa Cruz de Tenerife, Spain; 9Hospital Universitario, Salamanca,
Spain; 10Hospital Puerta de Hierro, Majadahonda, Spain; 11Hospital Juan Ramon
Jimenez, Huelva, Spain; 12Hospital León, León, Spain; 13Hospital Bellvitge,
Barcelona, Spain; 14Hospital Virgen de la Salud, Toledo, Spain
Background: Percutaneous closure of atrial septal defects (ASD) has established as
treatment of choice in most patients. Large and complex defects (multiperforated, rim
deficient, septal aneurysm) often require very large devices. Success rate, incidence
of early and late complications and potential predictors of failure in this setting are not
well known.
Methods: Multicenter registry of adult patients with an ASD who have undergone
percutaneous intervention with large devices (from 26 to 40 mm). Clinical,
echocardiographic and procedural data were analyzed, as well as clinical follow-up.
All data were collected retrospectively.
Results: We included 302 adult patients from 14 hospitals, mean age 48 years (17-79),
62% females, 86% were in sinus rhythm. ASD median size was 24 mm (unstretched),
16% had septal aneurysm, 6% were multiperforated, and 45% had at least one deficient
rim (28% retroaortic, 6% anterosuperior, 6% inferior, 5% posterior). Echocardiographic
imaging during intervention was intracardiac in 51%, and transesophageal/3D (TEE)
in 49%. Stretching balloon was used in 32% of defects (mean defect size 27±4 mm).
Most devices were Amplatzer ASD (99%), the rest were Occlutech (1%), with a mean
size of 31±4 mm. Immediate success was achieved in 91% of patients. The device was
not released in 13 patients (4,3%), and early embolization happened in 11 patients
(3,6%). In 4 patients (1,3%) significant device malposition was discovered early after
deployment. Other minor complications were atrial fibrillation (1%), cerebral ischemia
(0,7%) and cardiac tamponade (0,7%). No mortality was related to the procedure.
Follow-up has been 52±36 months. Late severe complications were embolization or
malposition (1,3%) and perforation (0,3%), and all of them required surgery. Atrial
tachyarrhythmias (7,7%) were the most frequent complications during follow-up.
Univariant analysis showed that an absent or deficient inferior rim is significantly
associated with lower success rate (p<0,05).
Conclusion: Transcatheter closure of large and complex ASD with large devices (≥26
mm) is feasible and safe, with a low rate of complications. Device not released and
early embolization were the main causes of failure. A deficient inferior rim is an
independent predictor of device failure.
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Percutaneous Paravalvular Leak Closure Abates Heart Failure Symptoms,
Reduces NT-proBNP Plasma Concentration and Left Ventricle Size
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Background: Paravalvular leak (PVL) is a complication of heart valves prostheses
implantation which may provoke heart failure (HF) and deteriorate patients’ survival.
Less invasive than surgical treatment, the percutaneous PVL closure is auspicious but
requires further investigation.
Methods: We enrolled 23 consecutive patients referred to our institution due to PVL
present at prosthesis in aortic (AV group; n=12) or mitral (MV group) position. All
patients presented with symptomatic heart failure corresponding to NYHA classes 4
(24%), 3 (75%) and 2 (1%). Consequently, percutaneous PVL closure procedures were
scheduled via transfemoral, transseptal or transapical access, depending on PVLs’
features. End diastolic and systolic values of left ventricle (LV) diameters (EDD, ESD)
and volumes (EDV, ESV) were obtained by transthoracic echocardiography and
indexed to body surface area (EDDi, ESDi, EDVi, and ESVi, respectively). PVL
closure was performed with Amplatzer Vascular Plugs II or III.NT-proBNP plasma
concentration and LV dimensions were determined initially and in one month follow-
up.
Results: The successful PVL closure rate was 83%. In majority of patients implantation
of a single plug proved sufficient but in 5 cases two were required. The mean procedure
time reached 68 minutes in AV group and 160 minutes in MV group. After a month
we noted a reduction from 3 to 1 in median NYHA class (p<0.05) and a drop in mean
NT-proBNP (pg/mL) plasma concentration from 870 to 345 (p<0.05) in all patients.
LV dimensions markedly decreased in AV group (EDVi: 122 vs. 85 ml*; ESVi: 47 vs.
36 ml*; EDDi: 32 vs. 32ml ESDi: 20 vs. 18ml*; *-p<0.05) while in MV group they
remained unaffected (EDVi: 90 vs 96ml; ESVi 39 vs. 42 ml; EDDi: 35 vs. 36 ml; ESDi:
23 vs. 22).
Conclusion: Percutaneous PVL closure improves exercise tolerance and reduces NT-
proBNP plasma concentration regardless of lesion original location. Additionally,
elimination of aortic PVL reduces left ventricle size.
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Background: Though percutaneous patent foramen ovale (PFO) closure is performed
with increasing frequency worldwide, certain risks such as thrombus formation and
incomplete endothelialization remain. The Spider™ PFO Occluder was designed to
minimize these risks. The aim of this clinical trial was to assess safety, efficacy and
technical handling of this novel ceramic-coated double-disc PFO occluder.
Methods: The Spider™ PFO occluder is a self-expandable double-disc device with a
ceramic coated nitinol wire mesh and an integrated expanded polytetrafluoroethylene
(ePTFE) membrane on the right atrial side and ceramic coated nitinol anchors and an
ePTFE patch on the left atrial side. Study patient assessments were conducted at
baseline, periprocedure and discharge and at one and six-month follow-up.
Results: Fifty-one patients (mean age 52 ± 14 years; 63% male) were enrolled in the
prospective, multicenter clinical trial. Implantation was successful in all patients. Mean
procedural time was 30.0 ± 8.6 minutes. No periprocedural or in-hospital complications
occurred. Total follow-up time ranged from 5 to 12 months. Four patients (8%) had
paroxysmal atrial fibrillation at one-month follow-up. One patient suffered a pulmonary
embolism at the 6-month follow-up. Otherwise, no procedure or device related adverse
events occurred. Importantly, there were no recurrent embolic events. At the one-month
follow-up 63% (32/51) of all patients had no residual shunt with contrast
transesophageal echocardiography during Valsalva maneuver. Of all patients who
underwent six-month follow-up to date 77% (36/47) had no residual shunt during
Valsalva maneuver.
Conclusion: Initial results with the novel Spider™ PFO occluder show that the device
is safe to use for percutaneous closure of PFO. Although the overall complication rate
was low, there was a high incidence of atrial fibrillation during the one month-follow
up. The closure rate needs further investigation.
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Percutaneous Transcatheter Pulmonary Valve Implantation Induces a
Reduction of B-Type Natriuretic Peptide at 30 days
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Beauloye, Agnes Pasquet
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Background: High levels of B-Type Natriuretic Peptide (BNP) in patients with
congenital heart disease (CHD) correlate with the right ventricular volume load and
predict poor outcome. Surgical pulmonary valve replacement induces an immediate
postoperative increase followed by a reduction of BNP levels at long term. The aim of
the present study was to evaluate whether transcatheter pulmonary valve implantation
has also an impact on BNP levels.
Methods: Patients treated in our institution by implantation of a transcatheter
pulmonary valve were prospectively included in the study. BNP was measured before,
24 hours and 30 days after the procedure. A cardiac magnetic resonance imaging was
performed at baseline and at 3 months.
Results: Between september 2010 and april 2011, 10 patients (7 males, mean age 17
± 3 yrs) were treated in our institution by transcatheter pulmonary valve implantation
using the Melody Valve. CHD was tetralogy of Fallot in 6 patients, common arterial
trunk in 2, transposition of the great arteries in 1 and previous Ross intervention in
another one. All the procedures were successfull with two complications (distal
pulmonary hemorrhage due to the stiff wire, treated successfully by coil embolization
and positive pressure ventilation).The transvalvular gradient decreased from 31 ± 14
to 10 ± 6 mmHg (p<0.0001) with no significant residual pulmonary regurgitation. BNP
significantly decreased from 42 ± 34 to 20 ± 16 pg/ml at 30 days without any significant
change at 24 hours (28 ± 19 pg/ml, p=NS vs baseline). Right ventricular volume
significantly decreased from 132 ± 25 ml/m squarre to 101 ± 25 ml/m squarre (p=0.02)
at 3 months follow-up. Decrease of BNP at 30 days (-27 ± 22 pg/ml) correlated well
with the reduction of right ventricular volume (-29 ± 25 ml/m squarre) at 3 months (r
= 0.59).
Conclusion: Percutaneous transcatheter pulmonary Melody valve is a safe and
effective procedure, inducing a decrease of BNP levels at 30 days and resulting in
reduced right ventricular volumes at 3 months.
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